Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant

Transmission of hepatitis C virus (HCV) to recipients of hematopoietic stem cell transplant (HSCT) occurs frequently from HCV viremic donors and causes complications. Here, we report the outcomes of 3 cases from our 265 allogeneic HSCTs, whose donors had HCV infections. Successful prevention of HCV...

Full description

Saved in:
Bibliographic Details
Published inTransplant infectious disease Vol. 16; no. 6; pp. 1003 - 1006
Main Authors Hsiao, H.‐H., Liu, Y.‐C., Wang, H.‐C., Wu, C.‐H., Cho, S.‐F., Hsu, J.‐F., Tsai, H.‐J., Hsiao, S.Y., Chang, C.‐S., Lin, S.‐F., Liu, T.‐C., Chuang, W.‐L., Yu, M.‐L.
Format Journal Article
LanguageEnglish
Published Denmark Wiley Subscription Services, Inc 01.12.2014
Subjects
Adult
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Drug Therapy, Combination
Female
HCV
hematopoietic stem cell transplantation
Hematopoietic Stem Cell Transplantation - adverse effects
Hepacivirus - isolation & purification
Hepatitis
Hepatitis C - drug therapy
Hepatitis C - transmission
Hepatitis C - virology
hepatitis C virus
HSCT
Humans
Interferon-alpha - administration & dosage
Interferon-alpha - therapeutic use
Male
Polyethylene Glycols - administration & dosage
Polyethylene Glycols - therapeutic use
Recombinant Proteins - administration & dosage
Recombinant Proteins - therapeutic use
Ribavirin - administration & dosage
Ribavirin - therapeutic use
RNA, Viral - blood
Stem cells
Tissue Donors
transmission prevention
Viral Load
Viremia
hematopoietic stem cell transplantation
hepatitis C virus
HCV
HSCT
transmission prevention
Online AccessGet full text

Cover

More Information
Summary:Transmission of hepatitis C virus (HCV) to recipients of hematopoietic stem cell transplant (HSCT) occurs frequently from HCV viremic donors and causes complications. Here, we report the outcomes of 3 cases from our 265 allogeneic HSCTs, whose donors had HCV infections. Successful prevention of HCV transmission was noted in 1 recipient by pretreatment of the donor with peginterferon/ribavirin to undetectable levels of HCV viremia before stem cell harvest. This case stressed the important role of effective antiviral therapy and HCV RNA seronegativity before cell harvest for prevention of HCV transmission in HSCT.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1398-2273
1399-3062
DOI:10.1111/tid.12306